Christoph Schliemann

A high‐affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo‐vasculature <i>in vivo</i>

Alessandra Villa, Eveline Trachsel, Manuela Kaspar et al. · International Journal of Cancer · 2008 · 233 citations

Medicine, Cancer Biology, Oncology +15

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

L. H. Schmidt, Andreas Kümmel, Dennis Görlich et al. · PLoS ONE · 2015 · 229 citations · Full text

Medicine, Immunology, Oncology +17

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Tim Sauer, Kathan Parikh, Sandhya Sharma et al. · Blood · 2021 · 217 citations · Full text

Life Sciences, Immunology, Oncology +14

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

Constanze Schneider, Thomas Oellerich, Hanna‐Mari Baldauf et al. · Nature Medicine · 2016 · 185 citations

Medicine, Oncology, Pharmacology +14

<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Franziska Taube, Julia Annabell Georgi, Michael Krämer et al. · Blood · 2021 · 164 citations · Full text

Medicine, Genetics, Molecular Genetics +8